BMS-984923

• CAT Number: I045525
• CAS Number: 1375752-78-5
• Molecular Formula: C22H15ClN2O2
• Molecular Weight: 374.82
• Purity: ≥95%
• Synonyms: (4R,5R)-5-(2-chlorophenyl)-4-[5-(2-phenylethynyl)pyridin-3-yl]-1,3-oxazolidin-2-one
• InChI: InChI=1S/C22H15ClN2O2/c23-19-9-5-4-8-18(19)21-20(25-22(26)27-21)17-12-16(13-24-14-17)11-10-15-6-2-1-3-7-15/h1-9,12-14,20-21H,(H,25,26)/t20-,21-/m1/s1
• InChIKey: IAYVUQJOKDFLAL-NHCUHLMSSA-N
• SMILES: C1=CC=C(C=C1)C#CC2=CC(=CN=C2)C3C(OC(=O)N3)C4=CC=CC=C4Cl

BMS-984923 (Cat No.: I045525) is an experimental small-molecule inhibitor developed by Bristol Myers Squibb that selectively targets the thyroid hormone receptor beta (TRβ). It is being investigated as a metabolic regulator for conditions such as nonalcoholic steatohepatitis (NASH), dyslipidemia, and related metabolic disorders. By activating TRβ in the liver, BMS-984923 can reduce cholesterol and triglyceride levels, improve hepatic lipid metabolism, and potentially reverse steatosis. Its selectivity minimizes side effects associated with thyroid hormone therapies, making it a promising therapeutic candidate.

Reference

[1]. Laura T Haas, et al. Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer’s Mouse Phenotypes. Cell Rep. 2017 Jul 5;20(1):76-88.
[Content Brief]

[2]. Hong Huang, et al. Oxazolidinone-based allosteric modulators of mGluR5: Defining molecular switches to create a pharmacological tool box. Bioorg Med Chem Lett. 2016 Sep 1;26(17):4165-9.
[Content Brief]